Adoptive transfer of cytomegalovirus/epstein-barr virus-specific immune effector cells for therapeutic and preventive/preemptive treatment of pediatric allogeneic cell transplant recipients

Journal of Pediatric Hematology/Oncology

Volumn 32, Issue 1, 2010, Pages e31-e37

  Dong, Lujia ^a   Gao, Zhi Yong ^a   Chang, Lung Ji ^a,c   Liang, Yin ^b   Tan, Xi You ^a   Liu, Jin Hong ^a   Yu, Xin Jian ^a   Yang, Fu hung ^c   Xie, Yi ^a   Lu, Dao Pei ^a  

^a FUDAN UNIVERSITY   (China)

^b Vectorite Biomedical Inc   (China)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Allogeneic hematopoietic cell transplant; CMV; Cytotoxic T cell; EBV

Indexed keywords

ACICLOVIR; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; FOSCARNET; GANCICLOVIR; RIBAVIRIN; SEMUSTINE; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE TRANSFER; ALLOGENIC BONE MARROW TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; CASE REPORT; CELL TRANSPLANTATION; CHILD; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DENDRITIC CELL; DRUG DOSE REDUCTION; EFFECTOR CELL; EPSTEIN BARR VIRUS; FEMALE; GRAFT FAILURE; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LUNG INFECTION; MALE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; VIRUS INFECTION;

ADOPTIVE TRANSFER; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DENDRITIC CELLS; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; MALE; PREMEDICATION; SURVIVAL RATE; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME;

EID: 75749122335     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181bf5e2d     Document Type: Article

References (16)

1. Klenovsek K, Weisel F, Schneider A, et al. Protection from CMV infection in immunodeficient hosts by adoptive transfer of memory B cells. Blood. 2007;110: 3472-3479
2. Komatsu H, Kogawa K, Nonoyama S. Bone marrow transplantation from a pediatric donor with a high frequency of cytomegalovirus-specific T-cells. J Med Virol. 2006;78: 1616-1623.
3. Heslop HE, Rooney CM. Adoptive immunotherapy of EBV lymphoproliferative diseases. Immunol Rev. 1997;157: 217.
4. O’Reilly RJ, Small TN, Papadopoulos E, et al. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev. 1997;157: 195.
5. Lucas KG, Burton RL, Zimmerman SE, et al. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood. 1998;91: 3654.
6. Gerritsen EJ, Stam ED, Hermans J, et al. Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA identical BMT in children. Bone Marrow Transplant. 1996;18: 377-382.
7. Lu DP, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by un-manipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes to HLA-identical sibling transplantation. Blood. 2006;107: 3065-3073.
8. + cell dose and disease status are important factors determining clinical outcomes in patients undergoing unmanipulated haploidentical blood and marrow transplantation after conditioning including antithymocyte globulin. Biol Blood Marrow Transplant. 2007;13: 1515-1524.
9. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92: 1549-1555.
10. Han S, Liang Y, Yang F, et al. Phenotype and functional analyses of therapeutic immune cells generated through interferon-gamma or CD137 selection versus dendritic cell activation approaches. Journal of Hematology & Oncology 2009;2: 34.
11. Micklethwaite K, Hansen A, Foster A, et al. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13: 707-714.
12. Cwynarski K, Ainsworth J, Cobbold M, et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood. 2001;97: 1232-1240.
13. Broers AE, van der Holt R, van Esser JW, et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood. 2000;95: 2240-2245.
14. + T cells. J Exp Med. 2005;201: 1031-1036.
15. Craddock C, Szydlo RM, Dazzi F, et al. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis. Br J Haematol. 2001;112: 228-236.
16. + T cell responses broaden over time after primary CMV infection in infants. J Infect Dis. 2007;195: 1789-1798.